Falcon Point Capital LLC decreased its stake in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 3.0% during the second quarter, Holdings Channel reports. The firm owned 672,302 shares of the specialty pharmaceutical company’s stock after selling 20,698 shares during the period. Falcon Point Capital LLC’s holdings in AMAG Pharmaceuticals were worth $12,370,000 as of its most recent filing with the SEC.

Other large investors have also recently modified their holdings of the company. BlackRock Inc. raised its stake in shares of AMAG Pharmaceuticals by 67,790.9% in the first quarter. BlackRock Inc. now owns 4,995,412 shares of the specialty pharmaceutical company’s stock valued at $112,647,000 after buying an additional 4,988,054 shares during the period. Vanguard Group Inc. raised its stake in AMAG Pharmaceuticals by 6.1% in the first quarter. Vanguard Group Inc. now owns 3,085,348 shares of the specialty pharmaceutical company’s stock worth $69,576,000 after buying an additional 176,832 shares during the period. State Street Corp raised its stake in AMAG Pharmaceuticals by 75.2% in the first quarter. State Street Corp now owns 2,522,059 shares of the specialty pharmaceutical company’s stock worth $56,876,000 after buying an additional 1,082,366 shares during the period. LSV Asset Management raised its stake in AMAG Pharmaceuticals by 34.0% in the first quarter. LSV Asset Management now owns 1,685,098 shares of the specialty pharmaceutical company’s stock worth $37,998,000 after buying an additional 427,238 shares during the period. Finally, Acadian Asset Management LLC raised its stake in AMAG Pharmaceuticals by 777.8% in the first quarter. Acadian Asset Management LLC now owns 1,226,690 shares of the specialty pharmaceutical company’s stock worth $27,659,000 after buying an additional 1,086,937 shares during the period.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) opened at 17.10 on Friday. AMAG Pharmaceuticals, Inc. has a 52-week low of $16.00 and a 52-week high of $36.83. The company’s market cap is $603.42 million. The firm’s 50-day moving average price is $19.06 and its 200-day moving average price is $20.82.

AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.58) by $0.18. The business had revenue of $158.39 million during the quarter, compared to the consensus estimate of $158.83 million. AMAG Pharmaceuticals had a negative net margin of 7.58% and a negative return on equity of 4.81%. The firm’s quarterly revenue was up 24.3% compared to the same quarter last year. During the same quarter last year, the firm earned $1.45 earnings per share. On average, equities analysts anticipate that AMAG Pharmaceuticals, Inc. will post ($1.37) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This article was originally published by Daily Political and is the property of of Daily Political. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/08/12/amag-pharmaceuticals-inc-amag-shares-sold-by-falcon-point-capital-llc.html.

AMAG has been the subject of a number of recent research reports. ValuEngine lowered AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, May 11th. Cowen and Company reissued a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Thursday. Zacks Investment Research raised AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $22.00 target price for the company in a research note on Tuesday, July 11th. Cantor Fitzgerald reissued a “hold” rating and issued a $23.00 target price on shares of AMAG Pharmaceuticals in a research note on Tuesday, May 2nd. Finally, BidaskClub raised AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $28.09.

In other AMAG Pharmaceuticals news, SVP Julie Krop sold 4,938 shares of the firm’s stock in a transaction dated Thursday, July 13th. The shares were sold at an average price of $20.00, for a total value of $98,760.00. Following the completion of the sale, the senior vice president now owns 28,336 shares of the company’s stock, valued at $566,720. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 3.80% of the stock is owned by company insiders.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Want to see what other hedge funds are holding AMAG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.